CLinical Experience Acquired with Raptiva super(+) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial

Background: The 12-week, double-blind, placebo-controlled, first-treatment (FT) CLEAR trial period demonstrated the efficacy-safety of efalizumab in moderate-to-severe plaque psoriasis, including refractory or contraindicated patients unsuitable for other systemic treatments. This study assessed the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal der Deutschen Dermatologischen Gesellschaft 2006-11, Vol.4 (11), p.947-956
Hauptverfasser:	Sterry, Wolfram, Stingl, Georg, Langley, Richard GB, Zacharie, Hugh, Lahfa, Morad, Giannetti, Alberto, Ferrandiz, Carlos, Sinclair, Rodney, Saurat, Jean-Hilaire
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!